Xunfei Healthcare Technology (SEHK:2506) Margin Worsening In 1H 2025 Tests Bullish Turnaround Narrative

Xunfei Healthcare Technology (SEHK:2506) has released its FY 2025 first half numbers, reporting revenue of C¥298.6 million with a basic EPS loss of C¥0.61 per share. Trailing twelve month figures show revenue of C¥915.0 million and a basic EPS loss of C¥0.54. Over the past three reported halves, revenue has moved from C¥229.2 million in 1H 2024 to C¥504.8 million in 2H 2024 and then to C¥298.6 million in 1H 2025, with basic EPS losses of C¥1.14, C¥0.03 and C¥0.61 respectively. Taken together, these results indicate expanding scale alongside continued margin pressure.

See our full analysis for Xunfei Healthcare Technology.

With the latest figures now available, the next step is to assess how this earnings profile compares with the prevailing growth and profitability narratives around the stock, and where those narratives might merit reconsideration.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM revenue nears C¥915 million while losses narrow

• On a trailing twelve month view, Xunfei Healthcare Technology booked C¥914.993 million in revenue with a net loss of C¥64.788 million, compared with an earlier trailing loss figure of C¥132.6 million on C¥733.984 million of revenue.
• What stands out for a more bullish angle is that five year losses reportedly narrowed at about 12.4% per year while revenue growth is described at 32.8% per year. However, the latest half still shows a C¥74.086 million loss on C¥298.552 million of revenue, which tests the optimistic view that growth alone will quickly translate into consistent profitability.
  • Supporters of the bullish narrative may point to the trailing loss of C¥64.788 million against C¥914.993 million of revenue as progress compared with the earlier trailing loss of C¥132.6 million on C¥733.984 million of revenue.
  • At the same time, the swing from a near breakeven loss of C¥2.947 million in 2H 2024 to a C¥74.086 million loss in 1H 2025 shows that the path to the forecast 104.84% yearly earnings growth is not yet visible in the reported halves.

When you see revenue and losses moving like this, it really helps to understand how different investors frame the story around growth, margins, and timing of profitability, not just the headline TTM figures. 📊 Read the what the Community is saying about Xunfei Healthcare Technology.

Mixed margin picture across recent halves

• Over the last three reported halves, revenue stepped from C¥229.205 million in 1H 2024 to C¥504.779 million in 2H 2024, then to C¥298.552 million in 1H 2025, while net losses shifted from C¥129.653 million to C¥2.947 million and then to C¥74.086 million.
• Bears focusing on profitability will see tension between the improvement in trailing twelve month losses and the uneven half year pattern, because the near breakeven 2H 2024 loss of C¥2.947 million was followed by a much wider C¥74.086 million loss in 1H 2025 even though revenue stayed in the C¥298 million to C¥504 million range.
  • Critics highlight that the EPS loss moved from C¥1.138875 in 1H 2024 to C¥0.025877 in 2H 2024, then back to C¥0.612898 in 1H 2025, suggesting that cost control and operating efficiency are not yet consistent across reporting periods.
  • At the same time, the trailing twelve month EPS loss of C¥0.54 sits between the 1H 2025 and 2H 2024 half year figures, which means bears can argue that the improvement trend over several years still coexists with meaningful volatility in nearer term margins.

Premium valuation meets tight cash runway

• The shares trade at HK$69.60 with an 8.1x P/S ratio, compared with a stated DCF fair value of HK$40.25 and an industry P/S average of 5.7x, while the company is flagged as having less than one year of cash runway.
• Skeptical investors looking at the more bearish angle will point out that the premium to the 5.7x industry P/S and to the HK$40.25 DCF fair value sits alongside ongoing losses of C¥64.788 million on a trailing twelve month basis and a reported cash runway of under one year, which makes any valuation premium heavily dependent on the forecast 32.8% revenue growth and 104.84% earnings growth actually showing up in future financials.
  • One concern is that the current P/S of 8.1x is below the 11.7x peer average yet still above the industry, so if revenue or earnings forecasts are not met, the valuation could move closer to the broader sector level.
  • Another bear argument is that with the business still loss making across the latest halves and less than a year of implied cash runway, any need for additional funding would add another layer for investors to weigh on top of the existing premium to DCF fair value.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Xunfei Healthcare Technology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the combination of a premium valuation and ongoing losses seems finely balanced, now may be a good time to review the details yourself and weigh both sides with 2 key rewards and 1 important warning sign

Explore Alternatives

Ongoing losses, uneven margins between recent halves, a premium P/S ratio and a short cash runway all point to higher business and funding risk for now.

If that mix of volatility and funding pressure feels uncomfortable, compare it with companies screened for stronger financial resilience and a steadier profile using the 278 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com